Ocular Therapeutix Inc OCUL

NAS: OCUL | ISIN: US67576A1007 30/04/2025

8,300 USD (+1,10%)

(+1,10%) 30/04/2025

Grafiek Ocular Therapeutix Inc

Grafiek Ocular Therapeutix Inc

1 dag1d 1,10%
1 week1w 5,06%
1 maand1m 26,91%
3 maanden3m 9,93%
6 maanden6m -20,12%
1 jaar1j 65,34%
5 jaar5j 44,35%

Ocular Therapeutix Inc in het nieuws

Toon enkel gratis nieuws

19 februari 2024 · AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis · Persbericht

31 oktober 2023 · AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery · Persbericht

13 april 2022 · AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery · Persbericht

Profiel Ocular Therapeutix Inc

Fabricage van farmaceutische preparaten

Farmaceutische producten: Andere

Gezondheidstechnologie

Website: www.ocutx.com

Hoofdzetel: Bedford, Massachusetts Verenigde Staten

CEO: Antony Mattessich

Werknemers: 274

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe